Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.

@article{Kreutzman2010MonooligoclonalTA,
  title={Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.},
  author={Anna Kreutzman and Vesa Juvonen and Veli Kairisto and Marja Ekblom and Leif Stenke and Ruth Seggewiss and Kimmo Porkka and Satu M Mustjoki},
  journal={Blood},
  year={2010},
  volume={116 5},
  pages={
          772-82
        }
}
In a proportion of patients with chronic myeloid leukemia (CML) being treated with dasatinib, we recently observed large granular lymphocyte (LGL) expansions carrying clonal T-cell receptor (TCR) gamma/delta gene rearrangements. To assess the prevalence and role of clonal lymphocytes in CML, we collected samples from patients (n = 34) at the time of diagnosis and during imatinib and dasatinib therapies and analyzed lymphocyte clonality with a sensitive polymerase chain reaction-based method of… 
View on PubMed
bloodjournal.org
165 Citations
Highly Influential Citations
3
Background Citations
60
Methods Citations
2
Results Citations
5

Figures and Tables from this paper

165 Citations

Large granular lymphocytosis during dasatinib therapy

The morphologic, phenotypic, clinical, and functional features of the LGL subsets amplified in vivo during dasatinib therapy are analyzed to suggest an aberrant immune response mediated by these LGLs is seen in some cases with fevers, colitis, and pleural effusions.

The longitudinal analysis of large granular lymphocytosis in patients with Philadelphia chromosome-positive leukemia treated with dasatinib

It is demonstrated that immunological condition at diagnosis may affect LGL lymphocytosis in some dasatinib-treated patients.

Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia.

Vδ1 and Vδ2 γδ T cell subsets in newly diagnosed chronic myeloid leukemia (CML) patients who had initiated tyrosine kinase inhibitor (TKI) therapy and the TCR clonality profiles showed in CML patients mostly polyclonal repertoires regardless of the TKI are analyzed.

Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation

Evidence is provided that dasatinib-associated LGL expansion is linked to CMV reactivation and a potential mechanism for this phenomenon is suggested, and features consistent with antigen-driven activation are suggested.

Dasatinib-induced anti-leukemia cellular immunity through a novel subset of CD57 positive helper/cytotoxic CD4 T cells in chronic myelogenous leukemia patients

The observations suggest that dasatinib induces the expansion of CD57+ Th-LGLs, which may play a crucial role in the dAsatinib-induced response against Philadelphia chromosome-positive leukemia.

Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients

LGL lymphocytosis during dasatinib treatment may be correlated with favorable molecular response, and with increased incidence of pleural effusions, in the clinical setting, CMV reactivation appears uncommon.

NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR–ABL-positive mice

It is concluded that CML is associated with quantitative and functional defects within the NK-cell compartment, which is reproduced by induced BCR–ABL expression in mice, and at identifying the mechanisms of NK- cell deficiency in CML and developing strategies to exploit NK cells for immunotherapy.

Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-α Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile

Data indicates that IFN-α treated CML patients in remission have increased numbers of NK-cells and clonal γδ+ T- cells and a unique plasma cytokine profile.

Characteristics of patients with development of large granular lymphocyte expansion among dasatinib-treated patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation.

The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia

The findings imply that the clonal landscape of large granular lymphocytic leukemia is more complex than considered before, and a substantial number of patients have multiple lymphocyte subclones harboring different STAT3 mutations, thus mimicking the situation in acute leukemia.
...

References

SHOWING 1-10 OF 78 REFERENCES

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

By inhibiting immunoregulatory kinases, dasatinib may induce a reversible state of aberrant immune reactivity associated with good clinical responses and a distinct adverse effect profile and include complete, unexpectedly long-lasting remissions in patients with advanced leukemia.

Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome

It is concluded that clonal T-cell expansion is common among all MDS prognostic subgroups and not associated with features linked previously to immunosuppression response.

The prognostic significance of T cell receptor β gene rearrangements and idiotype-reactive T cells in multiple myeloma

In patients with myeloma there was a good correlation between the presence of T cell receptor β gene rearrangements and idiotype-reactive T cells and patients with a rearranged T cell receptors β gene had a significantly better prognosis.

Clonal expanded TCR Vbeta T cells in patients with APL.

Investigation of the distribution and clonal expansion of T-cell receptor, Vss subfamily T-cells in patients with acute promyelocytic leukemia found skewed distribution andClonally expanded T- cells in the VSS subfamilies could be identified in Patients with APL.

Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation.

The increased response in patients after SCT suggests a quantitative explanation for the greater effect of allogeneic stem cell transplantation (SCT) and derive from memory T cells and occur at low frequencies in healthy individuals and at higher frequencies in patients with CML.

Opportunistic Infections Are Uncommon with Dasatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

It is indicated that OIs are rare in patients with CML-CP treated with dasatinib, and despite in vitro data suggesting immunosuppressive properties of dasarinib, there do not seem to be adverse clinical consequences with this agent.

Gamma Delta T Cells (GDTCs) to Eliminate Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia (CML) : A Pre-Clinical Model

It is observed that expanded GDTCs obtained from both healthy donors and Ph(+) CML patients exhibited specific cytotoxic activity against Ph+ lines, K562 and EM-2, indicating specificity against K562eGFP.

Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

There was a strong correlation between the presence of PR1-specific T cells and clinical responses after IFN-α and allogeneic BMT, providing for the first time direct evidence of a role for T-cell immunity in clearing malignant cells.

Low Risk of Infectious Events in Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Dasatinib.

This analysis shows that although many patients with CML in CP may develop infections during the course of therapy with dasatinib, these are overwhelmingly common infections, minor, and not related to d asatinib therapy.

T-Cell Large Granular Lymphocyte (T-LGL) Expansion Post Adult Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) – ‘A Prognostic Indicator for Improved Overall Survival’.

To the knowledge, this is the largest reported series of T-LGL expansion post allogeneic HSCT and there was a very low number of relapse of primary disease or death in patients with T- LGL expansion.
...